Financials
| 1st Quarter Results | May. 01, 2024 |
| GSK Annual Report 2023 on Form 20-F | Mar. 05, 2024 |
| GSK publishes Annual Report 2023 | Mar. 01, 2024 |
| Final Results | Jan. 31, 2024 |
| 3rd Quarter Results | Nov. 01, 2023 |
| 2nd Quarter Results | Jul. 26, 2023 |
| 1st Quarter Results | Apr. 26, 2023 |
Proxies
| Result of AGM | May. 08, 2024 |
| GSK Proxy Form 2024 | Mar. 25, 2024 |
| GSK AGM Notice 2024 | Mar. 25, 2024 |
| Notice of AGM | Mar. 25, 2024 |
| GSK Proxy Form 2023 | Mar. 27, 2023 |
| GSK AGM Notice 2023 | Mar. 27, 2023 |
| Publication of 2023 AGM Notice | Mar. 27, 2023 |
Ownership Update
| Director/PDMR Shareholding | Jul. 18, 2024 |
| Director/PDMR Shareholding | Jul. 16, 2024 |
| Director/PDMR Shareholding | Jul. 15, 2024 |
| Director/PDMR Shareholding | Jul. 12, 2024 |
| Director/PDMR Shareholding | Jun. 21, 2024 |
| Director/PDMR Shareholding | Jun. 12, 2024 |
| Director/PDMR Shareholding | May. 20, 2024 |
Announcements
| Blenrep EMA Filing Acceptance | Jul. 19, 2024 |
| GSK and CureVac collaboration restructured | Jul. 03, 2024 |
| Total Voting Rights | Jul. 01, 2024 |
| Statement: Zantac (ranitidine) litigation | Jun. 28, 2024 |
| Omjjara approved in Japan for myelofibrosis | Jun. 24, 2024 |
| EMA validates Jemperli marketing authorisation | Jun. 24, 2024 |
| Statement: Zantac (ranitidine) litigation | Jun. 11, 2024 |
Prospectuses
| GSK plc;GLAXOSMITHKLINE CAPITAL PLC;GSK Capital B.V.;GSK Capital K.K - Base prospectus (debt) | Sep. 07, 2022 |